- Nexavar is First Approved Systemic Therapy to Treat the Disease -



    Liver cancer is the sixth most common cancer in the world and the third

leading cause of cancer-related deaths globally.



    A recent study published in The New England Journal of Medicine showed

results of a Phase 3 trial demonstrating that Nexavar(R) (sorafenib)

tablets decreased the absolute risk of death by 31 percent in patients with

unresectable hepatocellular carcinoma (HCC), or liver cancer, versus

patients who received placebo. This represents a 44 percent improvement in

median overall survival for patients treated with Nexavar. Based on the

strength of these data, Nexavar was approved for HCC by the European Agency

for the Evaluation of Medicinal Products (EMEA) and by the U.S. Food and

Drug Administration (FDA) in October and November 2007, respectively.



    Hepatocellular carcinoma is the most common form of liver cancer and is

responsible for about 90 percent of the primary malignant liver tumors in

adults. In 2002, approximately 600,000 people died of liver cancer

including approximately 370,000 in China. South Korea and Japan, 57,000 in

the European Union, and 13,000 in the United States.






    SATELLITE FEEDS:

    Wednesday, July 23rd, 2008         Thursday, July 24th, 2008

    6:30 PM - 6:45 PM ET               1:00 PM - 1:15 PM ET

    Galaxy 25                          Galaxy 11

    C-Band                             C-Band

    Transponder 1                      Transponder 10

    Downlink Freq. 3720 Vertical       Downlink Freq. 3900 Vertical

    NEWS: Study in the NEJM Shows Nexavar(R) Helped Decrease Risk of Death

in Liver Cancer Patients



    FORMAT: B-roll and Soundbites



    ADDITIONAL RESOURCES: Video, contact information and more available at:

EMWNews.com/broadcast/31156/press.html" target="_new">http://www.EMWNews.com/broadcast/31156/press.html








    SOUNDBITES:

    * Josep Llovet, M.D., Co-principal investigator & Professor of Research

      Barcelona Clinic Liver Cancer (BCLC) Group, IDIBAPS, Liver Unit

      Hospital Clinic Barcelona & Director of Research, HCC Program,

      Associate Professor, Medicine Mount Sinai School of Medicine

    * Ray, Liver Cancer patient

    * David Reade, Liver Cancer Patient



    B-ROLL INCLUDES:

    * NEJM Page, Mechanism of Action, Nexavar Pill Bottles, Manufacturing

      Footage, Mount Sinai Exteriors, Lab Footage, Doctor Footage, Patient

      Lifestyle footage

    VIDEO PROVIDED BY: Bayer HealthCare Pharmaceuticals, Inc. and Onyx

Pharmaceuticals, Inc.



    Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations,

1-800-653-5313 EXT. 3